Jiangsu Hansoh Pharmaceutical Co., Ltd.
Quick facts
Marketed products
- ESPO
- Xgeva® · Oncology, Bone Health
Xgeva (denosumab) is a monoclonal antibody that inhibits RANKL, preventing osteoclast formation and bone resorption.
Phase 3 pipeline
- HS-10234 · Oncology
HS-10234 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HS-10241+ Almonertinib · Oncology
HS-10241 is a third-generation EGFR tyrosine kinase inhibitor designed to target EGFR mutations including common and uncommon variants, often combined with almonertinib (a third-generation EGFR-TKI) to enhance efficacy against resistant lung cancers. - HS-10296 · Oncology
HS-10296 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. - HS-20094 · Oncology
HS-20094 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival pathways. - PEG-Tα1 · Immunology; Infectious Disease
PEG-Tα1 is a pegylated thymosin alpha 1 that enhances immune function by promoting T-cell maturation and activation. - pegol-Sihematide · Hematology
Pegol-sihematide is a long-acting erythropoiesis-stimulating agent that promotes red blood cell production. - Pemetrexed + Cisplatin /Carboplatin · Oncology
Pemetrexed is a folate antagonist that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to cell death in rapidly dividing cancer cells. Cisplatin and Carboplatin are platinum-based chemotherapeutic agents that induce DNA crosslinks, causing cell death. - PEX168(100µg) · Diabetes
PEX168 is a long-acting GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. - PEX168(200µg) · Diabetes
PEX168 is a long-acting GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. - Placebo to match PEG-Tα1
This is a placebo control formulation designed to match the appearance and administration characteristics of PEG-Tα1 (pegylated thymosin alpha 1) for blinded clinical trial purposes.
Phase 2 pipeline
- EPO-018B
- HS-10342
- HS-10365 capsules
- HS-10383
- HS-10542 High Dose
- HS-10542 Low Dose · null
HS-10542 Low Dose is a small molecule drug that targets the molecular target. - HS-20117
- Sustained-Release Desvenlafaxine Hydrochloride
- Sustained-Release Venlafaxine Hydrochloride
Phase 1 pipeline
- Aumolertinib；midazolam
- Azilsartan Trimethylethanolamine
- Cafusertib Hydrochloride
- Drug：HS-10510；
- Drug： Rosuvastatin
- HS-10241
- HS-10352
- HS-10353
- HS-10356
- HS-10360
- HS-10365
- HS-10370
- HS-10375
- HS-10376
- HS-10380
- HS-10381
- HS-10386
- HS-10398
- HS-10501 tablet
- HS-10502
- HS-10504
- HS-10506
- HS-10509
- HS-10511 Tablets
- HS-10516
- HS-10517 Dose 1
- HS-10518
- HS-10529
- HS-10542
- HS-10561
- HS-10566
- HS-20090
- HS-20094 AI pen;
- HS-20094 MDV pen
- HS-20118
- HS-20122
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: